Microbiota-gut-brain axis multi-organ chip construction and applications in drug evaluation.

Area of Science:

• Neuroscience
• Microbiology
• Biotechnology

Background:

• The microbiota-gut-brain axis (MGBA) describes gut microbiota's (GM) impact on the central nervous system (CNS).
• Understanding MGBA is crucial for novel neurological disorder diagnosis and treatment.
• Current research requires advanced models to study complex cross-organ interactions.

Purpose of the Study:

• To review the theoretical framework and mechanistic insights of the MGBA.
• To highlight advances in multiorgan chip technologies for studying the MGBA.
• To underscore the application of these technologies in drug evaluation.

Main Methods:

• Utilizing microfluidic organ chips and bionic microphysiological systems.
• Developing "organ-on-a-chip" models (gut, blood-brain barrier, brain).
• Implementing multiorgan chip cascade technologies for integrated analysis.

Main Results:

• Microfluidic systems enable multidisciplinary assessment of drug effects on the MGBA.
• Bionic systems facilitate analysis of cross-organ interactions within the MGBA.
• Technology supports evaluation of pharmacokinetics, host-microbe coevolution, and neuroendocrine regulation.

Conclusions:

• MGBA multiorgan chip technologies represent a groundbreaking paradigm for translational medicine.
• These models are vital for multimodal cross-validation in pharmacodynamics, toxicology, and drug development.
• Future directions involve further development of MGBA multiorgan chip technologies.